Prolonged Grief Disorder: Diagnosis, Neurobiology, Cultural Variations, Risk Factors, and Evidence-Based Treatment

Grief is among the most universal human experiences, yet it remains one of the most clinically misunderstood. The death of a significant attachment figure triggers a complex psychobiological response that, for most individuals, follows a trajectory of gradual adaptation. However, for a substantial minority, this process derails — producing a chronic, debilitating condition now formally recognized in both the DSM-5-TR and ICD-11 as Prolonged Grief Disorder (PGD).

The formal recognition of PGD resolved decades of debate about whether intense, persistent grief constitutes a psychiatric disorder or merely a variant of normal suffering. The inclusion of PGD in the DSM-5-TR (2022) and the closely related Prolonged Grief Disorder in the ICD-11 (2019, effective 2022) marked a watershed moment in bereavement research and clinical practice. These classifications provide clinicians with validated diagnostic frameworks while acknowledging that grief itself is not pathological — only its derailment into a specific syndrome of persistent yearning, preoccupation, and functional impairment qualifies as a mental disorder.

This article provides a comprehensive clinical examination of grief and bereavement, differentiating normative grief from PGD. It covers the neurobiology of grief, epidemiological data, diagnostic criteria and differential diagnosis, cultural variations, risk factors, prognostic indicators, comorbidity patterns, and evidence-based treatments — including head-to-head efficacy comparisons where available.

Normal, or uncomplicated grief, is characterized by a constellation of emotional, cognitive, behavioral, and somatic responses to bereavement that, while potentially intense, follow an overall trajectory toward adaptation. Core features include waves of sadness, yearning for the deceased, intrusive memories, social withdrawal, sleep disruption, appetite changes, and periods of disbelief. Critically, these symptoms tend to diminish in intensity and frequency over the months following a loss, though they may resurge around anniversaries, holidays, or other reminders.

The Dual Process Model of Coping

The Dual Process Model (DPM), proposed by Stroebe and Schut (1999), offers the most empirically supported framework for understanding adaptive grief. The DPM posits that healthy grief involves oscillation between two orientations: loss-oriented coping (confronting the emotional pain of the loss, yearning, ruminating about the deceased) and restoration-oriented coping (attending to life changes necessitated by the loss, developing new identities, managing daily tasks). This oscillation is not merely a description of what happens — it appears to be functionally necessary. Individuals who become stuck predominantly in one orientation (typically loss-orientation) are at elevated risk for prolonged grief.

Timeline Considerations

Research consistently demonstrates that for most bereaved individuals, the acute intensity of grief symptoms diminishes substantially within 6–12 months. The landmark Yale Bereavement Study (Maciejewski et al., 2007), which followed 233 bereaved individuals longitudinally, found that acceptance was the most frequently endorsed psychological state at every time point assessed, even in the first month post-loss. Disbelief peaked at approximately one month, yearning at four months, anger at five months, and depression at six months — all declining thereafter. This study provided crucial empirical evidence against the popular but unsupported Kübler-Ross stage model, demonstrating that "acceptance" is not a final achievement but rather the dominant experience throughout normal grief.

Approximately 50–60% of bereaved individuals show a resilient trajectory — maintaining relatively stable psychological functioning throughout, with grief symptoms never reaching clinical thresholds. Another 20–30% experience a pattern of gradual recovery from initially elevated distress. These trajectories, identified by Bonanno and colleagues using latent growth mixture modeling, underscore that intense, disabling grief is not the norm but the exception.

DSM-5-TR Criteria for Prolonged Grief Disorder

The DSM-5-TR (APA, 2022) defines Prolonged Grief Disorder as a condition in which a bereaved individual experiences a persistent and pervasive grief response characterized by intense longing/yearning for the deceased or persistent preoccupation with the deceased. The full criteria are:

• Criterion A: The death of a person close to the bereaved at least 12 months ago (6 months for children and adolescents).
• Criterion B: Since the death, the development of a persistent grief response characterized by one or both: (1) intense yearning/longing for the deceased; (2) preoccupation with thoughts or memories of the deceased (in children, preoccupation may focus on circumstances of the death).
• Criterion C: Since the death, at least three of the following eight symptoms experienced to a clinically significant degree and nearly every day or to a marked degree for at least the last month: identity disruption, marked sense of disbelief about the death, avoidance of reminders that the person is dead, intense emotional pain related to the death, difficulty reintegrating into life, emotional numbness, feeling that life is meaningless, and intense loneliness.
• Criterion D: The disturbance causes clinically significant distress or impairment in social, occupational, or other important areas of functioning.
• Criterion E: The duration and severity of the response clearly exceed expected social, cultural, or religious norms for the individual's culture and context.

ICD-11 Criteria: Key Differences

The ICD-11 categorizes PGD under Disorders Specifically Associated with Stress (code 6B42) and requires a shorter time criterion of 6 months post-loss, compared to the DSM-5-TR's 12 months. The ICD-11 also places greater emphasis on the distinction between normative and culturally expected grief, though both systems include cultural caveat criteria. The ICD-11 requires persistent and pervasive longing for or preoccupation with the deceased, accompanied by intense emotional pain (e.g., sadness, guilt, anger, denial, blame, difficulty accepting the death, feeling of having lost part of oneself, inability to experience positive mood, emotional numbness, difficulty engaging in social or other activities).

Clinical Significance of the Time Criterion Discrepancy

The 6-month vs. 12-month threshold represents the most clinically significant divergence between the two major diagnostic systems. The DSM-5-TR's more conservative 12-month criterion was chosen to minimize false positives and ensure that clinicians are not pathologizing normal grief responses that may still be evolving. However, critics argue that requiring 12 months delays treatment access for individuals who are clearly suffering and impaired at 6–9 months. Empirical data from Prigerson and colleagues suggest that PGD can be reliably diagnosed as early as 6 months with good predictive validity for long-term impairment, lending support to the ICD-11 approach.

Grief engages and disrupts multiple interconnected neural systems. Neuroimaging and neurochemical research has begun to clarify why grief is experienced as such a profound psychobiological disruption — and why, for some individuals, this disruption becomes chronic.

The Reward and Attachment Circuitry

The most distinctive neurobiological feature of grief is the activation of the brain's reward and attachment circuitry. Mary-Frances O'Connor's pioneering neuroimaging work (2008, 2012) demonstrated that viewing photographs of the deceased activates the nucleus accumbens — a key hub of the mesolimbic dopamine reward system — specifically in individuals with prolonged grief but not in those with normal grief. This finding suggests that in PGD, the brain continues to encode the deceased as a source of potential reward, maintaining a persistent "craving" analogous in neural signature (though not identical in phenomenology) to the craving seen in substance use disorders. The ventral tegmental area (VTA), which projects dopaminergic neurons to the nucleus accumbens and prefrontal cortex, shows differential activation patterns in prolonged vs. uncomplicated grief.

The Default Mode Network and Prefrontal Cortex

Grief also engages the default mode network (DMN) — particularly the medial prefrontal cortex (mPFC), posterior cingulate cortex (PCC), and temporoparietal junction (TPJ) — regions involved in self-referential processing, mentalizing, and maintaining mental representations of others. In normal grief, activity in these regions gradually diminishes as the individual updates their internal model of the world to accommodate the absence of the deceased. In PGD, persistent hyperactivation of the DMN may reflect a failure of this updating process — the bereaved person's internal model continues to expect and "search for" the deceased.

The dorsolateral prefrontal cortex (dlPFC) and anterior cingulate cortex (ACC), critical for cognitive control and emotion regulation, show reduced activation or impaired connectivity in PGD. This pattern suggests diminished capacity to modulate the emotional intensity of grief-related cognitions — a finding consistent with the clinical observation that individuals with PGD report being overwhelmed by grief and unable to redirect their attention.

The Stress Response System: HPA Axis and Cortisol

Bereavement is one of the most potent activators of the hypothalamic-pituitary-adrenal (HPA) axis. Bereaved individuals, particularly those with prolonged grief, show elevated cortisol levels, with some studies demonstrating flattened diurnal cortisol rhythms similar to patterns seen in chronic stress and major depression. Chronic HPA axis activation contributes to the documented immunosuppressive effects of bereavement — including reduced natural killer cell activity and impaired lymphocyte proliferation — which may partly explain the well-established "widowhood effect" (elevated mortality risk in the first 6–12 months after spousal loss, estimated at a 22–41% increase in relative risk depending on the study).

Oxytocin and the Attachment System

The oxytocinergic system, central to pair-bonding and social attachment, is profoundly disrupted by loss. Oxytocin modulates the salience of social stimuli and the emotional significance of attachment figures. Emerging research suggests that individual differences in oxytocin receptor (OXTR) gene polymorphisms may influence vulnerability to prolonged grief — particularly the rs53576 G allele, which has been associated with greater sensitivity to social loss. However, this genetic research is still in its early stages and requires replication.

Serotonin, Neuroinflammation, and BDNF

The serotonergic system is implicated through its well-established role in mood regulation, but grief-specific serotonin research is limited. What is notable is that SSRIs show limited efficacy for the core yearning symptoms of PGD (as distinguished from co-occurring depressive symptoms), suggesting that the neurochemistry of grief is not reducible to serotonergic dysfunction. Emerging evidence implicates neuroinflammatory pathways — elevated pro-inflammatory cytokines (IL-6, TNF-α, CRP) have been documented in bereaved individuals, with higher levels correlating with more severe grief symptoms. Reduced levels of brain-derived neurotrophic factor (BDNF), critical for synaptic plasticity and memory reconsolidation, may impair the neural updating process necessary for grief resolution.

Genetic Vulnerability

Twin studies suggest that approximately 30–40% of the variance in grief intensity may be attributable to genetic factors. Beyond OXTR polymorphisms, variants in the serotonin transporter gene (5-HTTLPR) and genes involved in HPA axis regulation (e.g., FKBP5, NR3C1) are candidates for influencing vulnerability, though genome-wide association studies (GWAS) specific to PGD have not yet been conducted.

Epidemiological data on PGD have become increasingly refined as diagnostic criteria have been standardized.

Prevalence Estimates

The most commonly cited prevalence estimate for PGD among bereaved adults is approximately 10% (range: 7–15%), based on multiple studies using pre-DSM-5-TR criteria (typically the Prigerson criteria or the ICD-11 criteria). A comprehensive meta-analysis by Lundorff and colleagues (2017), synthesizing data from 14 studies (N > 8,000 bereaved individuals), estimated a pooled prevalence of approximately 9.8% using the Prigerson criteria. However, prevalence varies substantially by context:

• Natural death of an elderly spouse: approximately 7–10%
• Death of a child: approximately 10–25%, with some studies reporting rates as high as 30%
• Sudden or violent death (homicide, suicide, accident): approximately 15–25%
• Deaths due to disaster or mass violence: rates of 20–40% have been reported in some populations
• COVID-19 pandemic bereavement: early studies suggest elevated rates of 15–25%, attributable to circumstances of death (isolation, inability to say goodbye, mass bereavement) rather than the disease itself

Demographic Patterns

Women are consistently found to be at higher risk for PGD, with a roughly 2:1 female-to-male ratio in most studies — a pattern similar to major depressive disorder. Older adults show a higher absolute number of cases due to the higher frequency of bereavement but do not appear to be inherently more vulnerable per bereavement event. The prevalence of PGD across the lifespan remains understudied in children and adolescents, though emerging evidence suggests rates of approximately 5–10% among bereaved youth.

Population-Level Burden

Given that approximately 2.5 million deaths occur annually in the United States, each leaving an estimated 5–10 close survivors, the total number of newly bereaved individuals per year may exceed 12–25 million. Applying the 10% prevalence estimate suggests that approximately 1–2.5 million Americans may be experiencing PGD at any given time — a burden that far exceeds common assumptions and underscores the public health significance of this diagnosis.

One of the most critical clinical tasks in bereavement assessment is differentiating PGD from conditions that frequently co-occur with it. Misdiagnosis is common and leads to inappropriate treatment selection.

PGD vs. Major Depressive Disorder (MDD)

PGD and MDD share several features: sadness, social withdrawal, sleep disruption, difficulty concentrating, and functional impairment. However, they differ in several key respects:

• Core affective state: PGD is defined by yearning and longing for the deceased, while MDD is characterized by pervasive depressed mood and/or anhedonia. In PGD, positive emotions may be accessible when the deceased is remembered fondly; in MDD, anhedonia is typically pervasive.
• Self-esteem: In MDD, feelings of worthlessness and excessive guilt are directed globally at the self. In PGD, self-blame tends to be specifically related to the loss ("I should have been there").
• Content of preoccupation: In PGD, thoughts revolve around the deceased person and the loss. In MDD, negative cognitions are broader and often self-referential.
• Suicidality: In PGD, suicidal ideation, when present, is typically motivated by a desire to reunite with the deceased. In MDD, it is more often driven by hopelessness, self-loathing, or a desire to escape suffering.

Co-occurrence is common: approximately 50–60% of individuals with PGD also meet criteria for MDD. However, factor analytic studies consistently demonstrate that PGD and MDD represent distinct latent constructs, and PGD predicts impairment independently of comorbid depression.

PGD vs. Posttraumatic Stress Disorder (PTSD)

When the death occurs under traumatic circumstances (violence, accident, witnessing the death), PTSD and PGD may co-occur. Key distinctions:

• Intrusive cognitions in PGD tend to involve longing and memories of the relationship; in PTSD, intrusions involve re-experiencing the traumatic event itself (the manner of death, horrific images).
• Avoidance in PGD centers on reminders of the reality of the loss; in PTSD, avoidance centers on trauma cues.
• Emotional tone: PGD is dominated by separation distress (yearning, loneliness); PTSD is dominated by threat-related affect (fear, horror, hyperarousal).

Co-occurrence of PGD and PTSD has been estimated at approximately 25–40% following violent or traumatic losses. Clinicians must assess for both, as the combination is associated with significantly worse outcomes than either condition alone.

PGD vs. Adjustment Disorder

Adjustment disorder is a residual diagnostic category for clinically significant emotional or behavioral symptoms in response to an identifiable stressor. PGD is preferred when the specific symptom profile (yearning, preoccupation with the deceased, identity disruption) is met, as PGD has greater predictive validity, specificity, and treatment implications. Adjustment disorder should be reserved for grief-related distress that does not meet the PGD symptom profile but nonetheless exceeds expected norms.

Diagnostic Pitfalls

Common errors include: (1) diagnosing MDD and treating with antidepressants when the core issue is PGD, which responds poorly to standard antidepressant monotherapy; (2) assuming that any intense grief beyond 6 months is pathological, when normal grief can persist with variable intensity for years; (3) failing to assess for PGD in older adults, in whom grief symptoms may present somatically or as cognitive decline; and (4) applying DSM-5-TR criteria too rigidly to culturally diverse populations without considering culturally normative grief expressions.

Pre-Loss Risk Factors

• Insecure attachment style: This is among the most robust predictors of PGD. Individuals with anxious-preoccupied attachment styles show the highest risk (OR ≈ 2.0–3.5 in prospective studies), likely because they are more dependent on the attachment figure for emotional regulation. Avoidant attachment may also confer risk, particularly when it prevents emotional processing.
• Pre-existing psychiatric history: Prior MDD, anxiety disorders, and PTSD increase PGD risk approximately 2–3-fold.
• Female sex: Consistent risk factor across studies (OR ≈ 1.5–2.0).
• Low social support: Both perceived and structural social support deficits predict PGD.
• High dependency on the deceased: Especially relevant in spousal loss and parent-child loss.

Peri-Loss Risk Factors

• Mode of death: Violent deaths (suicide, homicide) carry the highest risk, followed by sudden/unexpected deaths. Suicide bereavement is associated with PGD rates of approximately 20–25% and carries additional burdens of stigma and self-blame.
• Caregiver burden: Prolonged caregiving before death can predispose to PGD, though the relationship is complex — some caregivers show anticipatory grief that is protective.
• Relationship to deceased: Loss of a child confers the highest risk, followed by spousal loss. Sibling and peer losses are often underrecognized as risk contexts.
• Lack of preparedness: Perceived unpreparedness for the death, even in cases of chronic illness, is a strong predictor.

Post-Loss Risk Factors

• Rumination: Repetitive, passive focus on the meaning and consequences of the loss (as opposed to active processing) is one of the strongest modifiable predictors of PGD.
• Avoidance: Both emotional avoidance (suppressing grief) and behavioral avoidance (avoiding reminders of loss or reality of loss) predict chronicity.
• Secondary stressors: Financial hardship, housing instability, and role changes following loss can impede grief adaptation.
• Absence of meaning-making: Inability to construct meaning or find benefit from the loss is consistently associated with worse outcomes.

Protective Factors and Good Prognostic Indicators

Factors associated with resilient bereavement trajectories include: secure attachment style, strong social support networks, capacity for positive emotion and cognitive flexibility, access to culturally appropriate rituals, pre-loss adaptive functioning, and the capacity for benefit-finding or meaning reconstruction. The ability to oscillate between loss-oriented and restoration-oriented coping (per the DPM) is a particularly important functional marker.

Grief is universal; its expression is not. Cultural factors profoundly shape the phenomenology, timeline, rituals, and social meaning of bereavement — and clinicians must be attuned to these variations to avoid both under-diagnosis and over-pathologization of PGD.

Cultural Variation in Grief Phenomenology

• Somatic expression: In many non-Western cultures, grief is primarily experienced and expressed somatically — as chest pain, headache, weakness, or "heart pain" — rather than through the psychological vocabulary of yearning, sadness, and meaning-making that Western diagnostic criteria emphasize. This is particularly well-documented in Chinese, South Asian, and some African and Indigenous communities.
• Continuing bonds vs. detachment: Western clinical models historically conceptualized grief resolution as requiring "letting go" of the deceased (influenced by Freud's concept of Trauerarbeit, or grief work). Many cultures, however, maintain active, ongoing relationships with the deceased through ancestor veneration (East Asian traditions), memorial practices (Mexican Día de los Muertos), or spiritual communication (various Indigenous traditions). Research now supports the view that continuing bonds can be adaptive or maladaptive depending on context — the critical variable is not whether the bond is maintained but whether it facilitates or impedes adaptation.
• Duration norms: Mourning periods vary enormously — from the Jewish shiva (7 days of intense mourning, followed by shloshim at 30 days and avelut at 12 months) to the 4 months and 10 days prescribed in some Islamic traditions for a widow (iddah) to open-ended mourning periods in other cultures. The DSM-5-TR's 12-month criterion may or may not align with culturally expected mourning durations.

Implications for Diagnosis

Both the DSM-5-TR and ICD-11 include cultural caveats requiring that the grief response exceed what is expected in the individual's cultural, religious, or social context. However, operationalizing this criterion remains challenging. Clinicians should:

• Conduct culturally informed assessments, ideally incorporating the DSM-5-TR's Cultural Formulation Interview (CFI)
• Consult with cultural informants or community leaders when uncertain
• Avoid assuming that any visible emotional expression (e.g., wailing, tearing of clothing) is pathological — or that stoicism indicates absence of grief
• Recognize that somatization of grief may not be captured by standard PGD assessment instruments developed in Western samples

Cross-Cultural Measurement Challenges

The most widely used PGD assessment instruments — the Inventory of Complicated Grief (ICG) and the Prolonged Grief Disorder-13 (PG-13) — were developed and validated primarily in Western (largely white, middle-class) samples. Cross-cultural validation efforts are ongoing but incomplete. Studies in Chinese, Japanese, African, and Latin American populations have yielded factor structures that are broadly similar but not identical to those in Western samples, with somatic and communal grief dimensions sometimes emerging as additional factors.

PGD is a high-comorbidity condition. The co-occurrence of other psychiatric disorders is the norm rather than the exception, and comorbidity substantially worsens prognosis.

Comorbidity Prevalence Estimates

• Major Depressive Disorder: 50–60% co-occurrence in individuals with PGD. As discussed, the two conditions are clinically and neurobiologically distinct, but their overlap complicates assessment and treatment. The presence of comorbid MDD is associated with more severe functional impairment and higher suicidal ideation.
• Posttraumatic Stress Disorder: 25–40% co-occurrence, rising to 50% or more in cases involving violent or traumatic deaths. The combination of PGD and PTSD has been termed "traumatic grief" in some literature and requires integrated treatment approaches.
• Generalized Anxiety Disorder and other anxiety disorders: approximately 25–35% co-occurrence. Separation anxiety features may be particularly prominent.
• Substance Use Disorders: approximately 10–20% co-occurrence, with alcohol use disorder being the most common. Substance use may function as a maladaptive avoidance strategy.
• Suicidality: PGD is an independent risk factor for suicidal ideation, with estimates of approximately 30–40% of PGD patients reporting significant suicidal thoughts. The risk is highest in those bereaved by suicide ("suicide-loss survivors"), where the incidence of PGD-related suicidal ideation may reach 50% or higher.

Medical Comorbidity

Bereavement, and PGD specifically, is associated with elevated risk for cardiovascular events (the "broken heart" phenomenon is not merely metaphorical — risk of myocardial infarction is elevated approximately 21-fold in the first 24 hours after a loss), immunosuppression, and increased healthcare utilization. Chronic PGD is associated with elevated systemic inflammation markers, disrupted sleep architecture, and increased rates of hypertension and cancer, though confounding by depression and health behaviors complicates causal inference.

Complicated Grief Treatment (CGT) / Prolonged Grief Disorder Therapy

The treatment with the strongest evidence base for PGD is Complicated Grief Treatment (CGT), developed by M. Katherine Shear at Columbia University. CGT is a 16-session manualized psychotherapy that integrates elements of cognitive-behavioral therapy, interpersonal therapy, and motivational interviewing, structured around the Dual Process Model framework. It includes:

• Imaginal revisiting of the story of the death (similar to prolonged exposure in PTSD treatment)
• Situational revisiting — graduated exposure to avoided people, places, and activities
• Restoration-oriented goals — concrete planning for re-engagement with life
• Continuing bonds work — imaginal conversations with the deceased to foster an adaptive ongoing connection

The landmark Shear et al. (2005) randomized controlled trial compared CGT (n = 95) to Interpersonal Psychotherapy (IPT, n = 86) for complicated grief. Results were striking:

• CGT response rate: 51% vs. IPT response rate: 28% (p = 0.02)
• CGT participants showed faster time to response and greater reduction in grief severity
• The number needed to treat (NNT) for CGT vs. IPT was approximately 4–5

A subsequent, larger RCT — the Shear et al. (2016) study published in JAMA Psychiatry — compared CGT alone, CGT + citalopram, citalopram alone, and placebo in 395 participants. Key findings:

• CGT + citalopram response rate: 54.6%
• CGT + placebo response rate: 46.0%
• Citalopram alone response rate: 28.3%
• Placebo alone response rate: 24.5%
• CGT (regardless of medication status) was significantly superior to no CGT. Citalopram added modest benefit primarily for co-occurring depressive symptoms, not for core grief symptoms.

Cognitive-Behavioral Therapy (CBT) for Grief

Several CBT-based grief interventions have demonstrated efficacy. Boelen and colleagues developed a CBT protocol that targets maladaptive grief cognitions (catastrophizing, self-blame) and avoidance behaviors. In an RCT (Boelen et al., 2007), CBT outperformed supportive counseling with a large effect size (d = 0.74 for grief symptom reduction). Exposure-based components appear to be particularly critical — a dismantling study found that CBT with exposure was superior to CBT with cognitive restructuring alone.

Pharmacotherapy

The evidence for pharmacotherapy as a standalone treatment for PGD is limited and largely disappointing:

• SSRIs (escitalopram, citalopram, paroxetine): Show minimal efficacy for core PGD symptoms (yearning, preoccupation, identity disruption). They may reduce comorbid depressive and anxiety symptoms, which is clinically useful but does not address the disorder's defining features. In the Shear et al. (2016) study, citalopram alone was not significantly better than placebo for grief outcomes.
• Tricyclic antidepressants: One early study (Pasternak et al., 1991) found that nortriptyline improved depressive symptoms in bereaved elderly but did not reduce grief-specific symptoms.
• Benzodiazepines: No evidence of efficacy for PGD, with significant risks of dependence and potential interference with emotional processing necessary for grief resolution.
• Naltrexone: An emerging area of research. Based on the hypothesis that grief yearning involves opioidergic and reward circuitry, a small pilot study has explored naltrexone for PGD symptoms. This research is too preliminary for clinical recommendations.

Head-to-Head Summary

The evidence clearly supports grief-specific psychotherapy (CGT or CBT for grief) as the first-line treatment for PGD. Antidepressant medication may be a useful adjunct for comorbid depression but should not be relied upon as monotherapy for PGD. The NNT for CGT vs. non-specific therapy is approximately 4–5, which compares favorably to many well-established treatments in psychiatry (for reference, the NNT for SSRIs vs. placebo in MDD is approximately 7–8).

Internet-Based and Guided Self-Help Interventions

Given the scale of the unmet need, internet-based CBT interventions for PGD have been developed and tested, particularly by Wagner, Knaevelsrud, and Maercker. RCTs of internet-based grief therapy have demonstrated moderate-to-large effect sizes (d = 0.5–1.0) compared to waitlist controls, with gains maintained at follow-up. These interventions offer potential for scaling treatment to underserved populations, though they are less well-established than face-to-face CGT.

Accurate assessment is fundamental to appropriate diagnosis and treatment monitoring. Several validated instruments are available:

• Inventory of Complicated Grief (ICG): A 19-item self-report measure developed by Prigerson et al. (1995). A cutoff score of ≥25 (later revised to ≥30 in some studies) identifies probable PGD with good sensitivity and specificity. This is the most widely used research instrument.
• Prolonged Grief Disorder Scale (PG-13): A 13-item measure specifically aligned with the Prigerson consensus criteria. Designed for diagnostic classification as well as symptom severity monitoring.
• Brief Grief Questionnaire (BGQ): A 5-item screening tool suitable for primary care and community settings. Items assess difficulty accepting the death, interference with functioning, and imagery-based distress.
• Traumatic Grief Inventory – Self-Report Plus (TGI-SR+): Developed by Boelen and Smid, this instrument assesses both DSM-5-TR and ICD-11 PGD criteria and is increasingly used in European research.
• Structured Clinical Interview approaches: Semi-structured interviews aligned with DSM-5-TR or ICD-11 criteria are the gold standard for diagnosis, though they are time-intensive.

Clinicians should use assessment instruments alongside clinical judgment, paying particular attention to functional impairment and cultural context that instruments may not fully capture.

Despite significant advances, the field of bereavement science faces several unresolved questions and methodological challenges:

Unresolved Questions

• Optimal timing of intervention: Should treatment be offered at 6 months (ICD-11) or 12 months (DSM-5-TR)? Does early intervention (3–6 months) prevent PGD in high-risk individuals, or does it constitute unnecessary pathologization? The preventive intervention literature is mixed — universal bereavement interventions show negligible effects, while targeted interventions for high-risk individuals show promise (effect sizes of d = 0.3–0.5 in indicated prevention trials).
• Biomarkers: No validated biomarkers for PGD exist. While neuroimaging findings (nucleus accumbens activation, DMN hyperconnectivity) are scientifically informative, they are not yet clinically actionable. Cortisol patterns and inflammatory markers are candidates but lack diagnostic specificity.
• Pharmacotherapy development: The failure of existing psychotropic medications to address core PGD symptoms points to the need for novel pharmacological approaches. The opioid system, oxytocin system, and glutamatergic/NMDA pathways (given the memory reconsolidation hypothesis) are under investigation. Psilocybin-assisted therapy for grief has entered early-phase clinical trials, based on its capacity to promote emotional openness and meaning-making, but efficacy data are not yet available.
• Digital and AI-assisted interventions: Chatbots, virtual reality memorial experiences, and AI-generated voice or image recreations of the deceased are emerging technologies with unknown psychological consequences. The ethical and clinical implications of these technologies are being debated but far outpace empirical evaluation.
• Grief in marginalized populations: Disenfranchised grief — grief that is not socially acknowledged (e.g., loss of an ex-partner, miscarriage, pet loss, loss due to dementia, loss within LGBTQ+ partnerships in unsupportive contexts) — remains understudied. PGD diagnostic frameworks have not been systematically validated in these contexts.

Methodological Limitations

• Most PGD treatment trials are relatively small (N < 400) and conducted in Western, high-income settings
• Long-term follow-up data (beyond 12–18 months post-treatment) are sparse
• Head-to-head comparisons between CGT and CBT for grief have not been conducted — both approaches have been tested primarily against non-specific comparators or waitlist controls
• The contribution of non-specific therapeutic factors (therapeutic alliance, validation, social support) vs. grief-specific techniques remains incompletely disentangled
• Pediatric and adolescent PGD treatment trials are in their infancy

Prolonged Grief Disorder is a distinct, prevalent, and debilitating psychiatric condition that is now formally recognized in both major diagnostic systems. Clinicians working with bereaved populations should be aware of the following key takeaways:

• Most grief is normal and self-limiting. Approximately 85–90% of bereaved individuals will adapt without clinical intervention. Grief, even when intense, should not be reflexively pathologized.
• PGD is real and identifiable. Approximately 10% of bereaved adults develop PGD, characterized by persistent yearning, preoccupation with the deceased, and functional impairment exceeding cultural norms at ≥12 months (DSM-5-TR) or ≥6 months (ICD-11).
• PGD is not depression. While frequently comorbid with MDD and PTSD, PGD is a distinct syndrome with different core features, neurobiological underpinnings, and treatment response profiles. Standard antidepressant monotherapy is insufficient.
• Grief-specific psychotherapy is the first-line treatment. Complicated Grief Treatment (CGT) has the strongest evidence base, with an NNT of approximately 4–5 and response rates of approximately 45–55%. CBT-based grief interventions are also effective. Pharmacotherapy should be reserved for comorbid conditions.
• Cultural humility is essential. The phenomenology, timeline, and expression of grief vary across cultures. Clinicians must use culturally informed assessment and avoid applying Western normative frameworks uncritically.
• Routine screening in high-risk populations — particularly following child loss, suicide bereavement, violent deaths, and pandemic-related deaths — is warranted, using brief instruments such as the BGQ or ICG.
• Comorbidity assessment is mandatory. Given the high rates of co-occurring MDD, PTSD, substance use, and suicidality, comprehensive psychiatric evaluation should accompany any PGD diagnosis.